Seetharam Reddy assumes charge as the Jt. Director of DGFT Vijayawada

Seetharam Reddy assumes charge as the Jt. Director of DGFT Vijayawada

The Joint Director of the new Vijayawada DGFT office, will work from Hyderabad for the first three months.

Jayarama Emani | The Dollar Business Vijayawada---The-Dollar-Business As reported in The Dollar Business on February 27, 2015 (https://in.thedollarbusiness.com/news/seetharam-reddy-likely-to-be-the-new-joint-director-of-dgft-vijayawada/15134), G Seetharam Reddy, assumed charge as the Joint Director of DGFT (Directorate General of Foreign Trade), Vijayawada. Reddy participated in a panel discussion on “An overview of Foreign Trade Policy 2015-20 – Its impact on Pharma Sector,” here in Hyderabad on April 15, 2015. The event was organised by the Pharmaceuticals Export Promotion Council of India (Pharmexcil). Speaking exclusively to The Dollar Business, Reddy said, “It is good to be back in the home State after 13 years and that too being away from DGFT for the last five years.” The Joint Director who belongs to the Indian Trade Services (ITS) Batch of 1989 and has worked at DGFT Hyderabad and DGFT Visakhapatnam in the past, added, “I will be working out of Hyderabad office for the next three months and then move to Vijayawada.” Joint Director, DGFT Hyderabad, S B S Reddy in his address, said “The new Foreign Trade Policy – 2015 was formulated with the focus on international trade to support India’s ‘Make in India’ campaign and to facilitate ‘ease of doing business’ for the stakeholders involved,” and added, “Under the EPCG (Export Promotion Capital Goods) Scheme, the specific export obligation for domestic procurement has been reduced from 90% to 75% of the normal export obligation. This is subject to other conditions as specified in the policy.” The policy has also restricted clubbing of authorization only in cases where endorsed products on the authorisation are same or similar. The period for maintenance of records after redemption of authorisations has been reduced to two years, Reddy said. Director General of Pharmexcil, Dr P V Appaji, Sanjay Lunia, Partner, Corporate India Advisors and S Suryanarayana, Director, Dr Reddy’s Laboratories also spoke on the occasion.    

This article was published on April 15, 2015 – 9.45 pm IST.